James P Mackin Net Worth
Track Major Insider Updates On X/TwitterLast Updated: 1 day, 16 hours ago
James P Mackin has an estimated net worth of at least $37.2 million*, as of Oct. 7, 2026. They own 877,275 shares of AORT stock. They have sold 648,310 shares of AORT stock since 2021, for an estimated $17.9 million.
James P Mackin $AORT SEC Form 4 Insider Trading
James P Mackin has filed a total of 31 insider trades in $AORT since 2021. Their most recent trade was a sale of 70,000 shares, made on Aug 19, 2026. Their largest trade was a sale of 70,700 shares, made on Mar 06, 2025. We estimate that they now own 877,275 shares of $AORT, worth an estimated $19.4 million.
Insider Trading at $AORT
There have been a total of 225 insider trades reported at $AORT since 2021, with 0 shares purchased and 1.4 million shares sold. The most active insider traders in $AORT stock have been Jean F Holloway, Marshall S. Stanton, and James P Mackin. The most recent trade was a sale of 11,480 shares reported by ANDREW M GREEN (SVP, Regulatory and Quality), made on Sep 10, 2026.
History of Insider Stock Trades by James P Mackin
| Company Ticker | Purchase / Sale | Shares | Date | Disclosed (EST) |
|---|---|---|---|---|
AORT
|
Sale | 70,000 | Aug 19, 2026 | Aug. 20, 2026, 2:11 p.m. |
AORT
|
Sale | 17,887 | Mar 03, 2026 | March 4, 2026, 7:44 p.m. |
AORT
|
Sale | 14,911 | Mar 02, 2026 | March 3, 2026, 4:02 p.m. |
AORT
|
Sale | 13,936 | Feb 24, 2026 | Feb. 25, 2026, 6:34 p.m. |
AORT
|
Sale | 20,962 | Feb 23, 2026 | Feb. 25, 2026, 6:34 p.m. |
AORT
|
Sale | 30,921 | Dec 03, 2025 | Dec. 4, 2025, 9:54 p.m. |
AORT
|
Sale | 30,921 | Dec 02, 2025 | Dec. 3, 2025, 8:27 p.m. |
AORT
|
Sale | 34,210 | Nov 13, 2025 | Nov. 14, 2025, 1:09 p.m. |
AORT
|
Sale | 17,580 | Nov 10, 2025 | Nov. 12, 2025, 9:08 p.m. |
AORT
|
Sale | 12,500 | Aug 15, 2025 | Aug. 19, 2025, 11:28 a.m. |
AORT
|
Sale | 17,739 | Mar 06, 2025 | March 10, 2025, 5:18 p.m. |
AORT
|
Sale | 70,700 | Mar 06, 2025 | March 10, 2025, 5:18 p.m. |
AORT
|
Sale | 13,784 | Feb 24, 2025 | Feb. 26, 2025, 3 p.m. |
AORT
|
Sale | 6,812 | Feb 24, 2025 | Feb. 26, 2025, 3 p.m. |
AORT
|
Sale | 4,896 | Feb 24, 2025 | Feb. 26, 2025, 3 p.m. |
AORT
|
Sale | 16,664 | Feb 24, 2025 | Feb. 26, 2025, 3 p.m. |
AORT
|
Sale | 13,996 | Mar 05, 2024 | March 7, 2024, 7:20 p.m. |
AORT
|
Sale | 4,837 | Feb 27, 2024 | Feb. 29, 2024, 6:36 p.m. |
AORT
|
Sale | 13,168 | Feb 26, 2024 | Feb. 28, 2024, 6:22 p.m. |
AORT
|
Sale | 18,144 | Feb 26, 2024 | Feb. 28, 2024, 6:22 p.m. |
AORT
|
Sale | 10,088 | Feb 20, 2024 | Feb. 22, 2024, 6:08 p.m. |
AORT
|
Sale | 2,756 | Feb 20, 2024 | Feb. 22, 2024, 6:08 p.m. |
AORT
|
Sale | 59,225 | Feb 20, 2024 | Feb. 22, 2024, 6:08 p.m. |
AORT
|
Sale | 9,990 | Mar 02, 2023 | March 3, 2023, 7:07 p.m. |
AORT
|
Sale | 12,645 | Feb 27, 2023 | March 1, 2023, 2:36 p.m. |
AORT
|
Sale | 9,985 | Feb 27, 2023 | March 1, 2023, 2:36 p.m. |
AORT
|
Sale | 56,500 | Feb 14, 2023 | Feb. 16, 2023, 6:36 p.m. |
AORT
|
Sale | 10,639 | Feb 10, 2022 | Feb. 11, 2022, 9:41 a.m. |
AORT
|
Sale | 10,638 | Feb 09, 2022 | Feb. 11, 2022, 9:41 a.m. |
AORT
|
Sale | 10,638 | Feb 08, 2022 | Feb. 10, 2022, 8:53 a.m. |
AORT
|
Sale | 10,638 | Feb 07, 2022 | Feb. 8, 2022, 5:38 p.m. |
$AORT Executives and Stock Owners with Insider Trades
-
Jean F Holloway, SVP, General Counsel
-
Marshall S. Stanton, SVP, Clinical & MD Affair
-
James P Mackin, President & CEO
-
Amy Horton, VP, Chief Accounting Officer
-
John E Davis, Chief Commercial Officer
-
Matthew A Getz, VP, Human Resources
-
Andrew M Green, VP Regulatory
-
Dennis B Maier, SVP, Operations
-
Rochelle L. Maney, VP, Quality
-
Andrew M Green, SVP, Regulatory and Quality
-
Lance A Berry, EVP, COO, CFO & Treasurer
-
David Ashley Lee, Executive VP, COO & CFO
-
John E Davis, Senior VP, Global Sales
-
Florian Tyrs, VP, Global Operations
-
Lance A Berry, Executive VP, CFO
*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.